Cross-sectional study of the prevalence, causes and management of hospital-onset diarrhoea

Published date: October 2019

Additional Information: Funding Information: Damian Mawer received a fellowship grant from the Healthcare Infection Society to undertake this work. Mark Wilcox reports grants and personal fees from Actelion , grants and personal fees from Cubist , grants and personal fees from Astellas , grants and personal fees from Merck , grants and personal fees from Sanofi-Pasteur , grants and personal fees from Summit , grants and personal fees from Seres , grants and personal fees from Biomerieux , grants from Da Volterra , personal fees from Valneva , personal fees and other from Alere , grants and personal fees from Qiagen , grants and personal fees from Pfizer , other from Astellas Pharma , non-financial support from Astellas Pharma, personal fees from Ferring , personal fees from Synthetic Biologics , during the conduct of the study; personal fees from Astra Zeneca , personal fees from Nabriva , personal fees from Pfizer , personal fees from Roche , personal fees from The Medicine Company , grants and personal fees from Abbott , personal fees from Basilea , grants and personal fees from European Tissue Symposium , personal fees from Bayer , personal fees from Allergan , personal fees from Menarini , personal fees from Motif Biosciences , grants and personal fees from Paratek , personal fees from AiCuris , personal fees from Antabio , personal fees from Spero , grants and personal fees from Tetraphase , grants and personal fees from Surface Skins , outside the submitted work. None of the other authors have any conflicts of interest to declare. Funding Information: Damian Mawer received a fellowship grant from the Healthcare Infection Society to undertake this work. Mark Wilcox reports grants and personal fees from Actelion, grants and personal fees from Cubist, grants and personal fees from Astellas, grants and personal fees from Merck, grants and personal fees from Sanofi-Pasteur, grants and personal fees from Summit, grants and personal fees from Seres, grants and personal fees from Biomerieux, grants from Da Volterra, personal fees from Valneva, personal fees and other from Alere, grants and personal fees from Qiagen, grants and personal fees from Pfizer, other from Astellas Pharma, non-financial support from Astellas Pharma, personal fees from Ferring, personal fees from Synthetic Biologics, during the conduct of the study; personal fees from Astra Zeneca, personal fees from Nabriva, personal fees from Pfizer, personal fees from Roche, personal fees from The Medicine Company, grants and personal fees from Abbott, personal fees from Basilea, grants and personal fees from European Tissue Symposium, personal fees from Bayer, personal fees from Allergan, personal fees from Menarini, personal fees from Motif Biosciences, grants and personal fees from Paratek, personal fees from AiCuris, personal fees from Antabio, personal fees from Spero, grants and personal fees from Tetraphase, grants and personal fees from Surface Skins, outside the submitted work. None of the other authors have any conflicts of interest to declare.Damian Mawer was funded by the Healthcare Infection Society during the work. Jordan Skittrall is funded by a National Institute for Health Research Academic Clinical Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors would like to thank the following for their contribution to this study: Graziella Kontkowski (from UK C. difficile Support) provided insights into the importance of HOD from a patient perspective; in Leeds, Dermot Burke, Clare Donnellan and Claire Berry; in Papworth, Margaret Gillham, Helen Wickenden and Victoria Stoneman; in Belfast, Michelle Copeland; and in Hampshire Hospitals NHS Foundation Trust, Hazel Gray. Funding Information: Damian Mawer was funded by the Healthcare Infection Society during the work. Jordan Skittrall is funded by a National Institute for Health Research Academic Clinical Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Publisher Copyright: © 2019 The Healthcare Infection Society Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

Related URLs:

• http://www.scopus.com/inward/r...D=8YFLogxK

Keywords: Clostridium difficile, Diarrhoea, Hospital acquired, Hospital onset, Nosocomial

Local EPrints ID: 447855

URI: http://eprints.soton.ac.uk/id/eprint/447855

DOI: doi:10.1016/j.jhin.2019.05.001

ISSN: 0195-6701

PURE UUID: 44d208d5-87ca-4ece-8454-313dd7c583d8

ORCID for A. Kennedy: orcid.org/0000-0003-4570-9104

ORCID for K. Saeed: orcid.org/0000-0003-0123-0302

Date deposited: 24 Mar 2021 18:30

Last modified: 18 Mar 2024 03:52